Neil Parrott
Overview
Explore the profile of Neil Parrott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
1478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozbey A, Meneses-Lorente G, Simmons B, McCallum S, Annaert P, Parrott N, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39934586
Background And Objectives: This study investigates the pharmacokinetics (PK) of entrectinib and its metabolite M5 (CYP3A4 substrates) in patients with hepatic impairment (HI) and applies physiologically based pharmacokinetic (PBPK) modelling...
2.
Reddy M, Cabalu T, de Zwart L, Ramsden D, Dowty M, Taskar K, et al.
Clin Pharmacol Ther
. 2024 Oct;
117(2):403-420.
PMID: 39422118
Physiologically-based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug-drug interactions (DDIs) with the potential to streamline or reduce clinical trial burden if predictions can be made with...
3.
Holzem F, Parrott N, Schaffland J, Brandl M, Bauer-Brandl A, Stillhart C
J Pharm Sci
. 2024 Jul;
113(10):3054-3064.
PMID: 39059554
Enabling drug formulations are often required to ensure sufficient absorption after oral administration of poorly soluble drugs. While these formulations typically increase the apparent solubility of the drug, it is...
4.
Umehara K, Parrott N, Schindler E, Legras V, Meneses-Lorente G
Clin Pharmacol Ther
. 2024 Jul;
116(4):1130-1140.
PMID: 39023380
Physiologically based pharmacokinetic (PBPK) models of entrectinib and its equipotent metabolite, M5, were established in healthy adult subjects and extrapolated to pediatric patients to predict increases in steady-state systemic exposure...
5.
6.
Ozbey A, Keemink J, Wagner B, Pugliano A, Krahenbuhl S, Annaert P, et al.
Drug Metab Dispos
. 2024 Apr;
52(7):614-625.
PMID: 38653501
Hepatic impairment, due to liver cirrhosis, decreases the activity of cytochrome P450 enzymes (CYPs). The use of physiologically based pharmacokinetic (PBPK) modeling to predict this effect for CYP substrates has...
7.
Milani N, Parrott N, Galetin A, Fowler S, Gertz M
CPT Pharmacometrics Syst Pharmacol
. 2024 Feb;
13(4):524-543.
PMID: 38356302
Organ-on-a-chip (OoC) systems are a promising new class of in vitro devices that can combine various tissues, cultured in different compartments, linked by media flow. The properties of these novel...
8.
Darlow C, Parrott N, Peck R, Hope W
CPT Pharmacometrics Syst Pharmacol
. 2023 Dec;
13(3):464-475.
PMID: 38108548
Antimicrobial resistance increasingly complicates neonatal sepsis in a global context. Fosfomycin and amikacin are two agents being tested in an ongoing multicenter neonatal sepsis trial. Although neonatal pharmacokinetics (PKs) have...
9.
Djebli N, Parrott N, Jaminion F, OJeanson A, Guerini E, Carlile D
CPT Pharmacometrics Syst Pharmacol
. 2023 Dec;
13(3):396-409.
PMID: 38044486
Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed-refractory diffuse large B cell lymphoma and other non-Hodgkin's lymphoma indications. By simultaneously binding human CD20-expressing tumor cells...
10.
Ozbey A, Fowler S, Leys K, Annaert P, Umehara K, Parrott N
Drug Metab Dispos
. 2023 Oct;
52(1).
PMID: 37879848
Physiologically-based pharmacokinetic (PBPK) modeling has become the established method for predicting human pharmacokinetics (PK) and drug-drug interactions (DDI). The number of drugs cleared by non-CYP enzyme metabolism has increased steadily...